Interpace Biosciences, Inc.
IDXG
Price:
$2.84
Market Cap:
$12.51M
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a geno...[Read more]
Industry
Medical - Diagnostics & Research
IPO Date
1998-05-20
Stock Exchange
PNK
Ticker
IDXG
PE Ratio
[2.58]
ROE
[-35.22%]
Current Ratio
[0.59]
Dividend Yield
[0%]
Enterprise Value
[11.59M]
Dividend History
The ROE as of December 2024 (TTM) for Interpace Biosciences, Inc. (IDXG) is -35.22%
According to Interpace Biosciences, Inc.’s latest financial reports and current stock price. The company's current ROE is -35.22%. This represents a change of 279.97% compared to the average of -9.27% of the last 4 quarters.
Interpace Biosciences, Inc. (IDXG) Historical ROE (quarterly & annually)
How has IDXG ROE performed in the past?
The mean historical ROE of Interpace Biosciences, Inc. over the last ten years is -43.78%. The current -35.22% ROE has changed -19.55% with respect to the historical average. Over the past ten years (40 quarters), IDXG's ROE was at its highest in in the September 2016 quarter at 506.63%. The ROE was at its lowest in in the June 2020 quarter at -324.63%.
Average
-43.78%
Median
-33.78%
Minimum
-204.51%
Maximum
90.09%
Interpace Biosciences, Inc. (IDXG) ROE by Quarter and Year
Discovering the peaks and valleys of Interpace Biosciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 468.31%
Maximum Annual ROE = 90.09%
Minimum Annual Increase = -156.98%
Minimum Annual ROE = -204.51%
| Year | ROE | Change |
|---|---|---|
| 2023 | -5.30% | -156.98% |
| 2022 | 9.30% | -73.25% |
| 2021 | 34.76% | -61.41% |
| 2020 | 90.09% | -144.05% |
| 2019 | -204.51% | 452.63% |
| 2018 | -37.01% | 21.08% |
| 2017 | -30.56% | -76.04% |
| 2016 | -127.58% | 46.47% |
| 2015 | -87.10% | 9.04% |
| 2014 | -79.88% | 468.31% |
Interpace Biosciences, Inc. (IDXG) Average ROE
How has IDXG ROE performed in the past?
The current ROE of Interpace Biosciences, Inc. (IDXG) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
12.92%
5-year avg
-15.13%
10-year avg
-43.78%
Interpace Biosciences, Inc. (IDXG) ROE vs. Peers
How is IDXG’s ROE compared to its peers?
Interpace Biosciences, Inc.’s ROE is greater than Intelligent Bio Solutions Inc. (-144.39%), greater than bioAffinity Technologies, Inc. (-202.71%), less than SeqLL Inc. (-0.04%), greater than Biocept, Inc. (-138.49%), less than FONAR Corporation (5.78%), greater than Burning Rock Biotech Limited (-60.83%), greater than Sera Prognostics, Inc. (-51.73%), greater than Olink Holding AB (publ) (-7.07%), greater than LumiraDx Limited (-1557.76%), less than HTG Molecular Diagnostics, Inc. (0%), greater than bioAffinity Technologies, Inc. (-202.71%), less than Genetron Holdings Limited (0%), greater than Exagen Inc. (-92.58%), greater than OncoCyte Corporation (-230.32%), greater than Personalis, Inc. (-69.12%), greater than iSpecimen Inc. (-139.25%), less than Trinity Biotech plc (79.32%),
| Company | ROE | Market cap |
|---|---|---|
| -144.39% | $5.88M | |
| -202.71% | $14.49M | |
| -0.04% | $0 | |
| -138.49% | $0 | |
| 5.78% | $95.52M | |
| -60.83% | $64.28M | |
| -51.73% | $286.88M | |
| -7.07% | $3.24B | |
| -1557.76% | $0 | |
| 0% | $1.06M | |
| -202.71% | $4.66M | |
| 0% | $127.29M | |
| -92.58% | $87.83M | |
| -230.32% | $37.37M | |
| -69.12% | $428.13M | |
| -139.25% | $2.77M | |
| 79.32% | $9.10M |
Build a custom stock screener for Interpace Biosciences, Inc. (IDXG) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Interpace Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Interpace Biosciences, Inc. (IDXG) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Interpace Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Interpace Biosciences, Inc.'s ROE?
How is the ROE calculated for Interpace Biosciences, Inc. (IDXG)?
What is the highest ROE for Interpace Biosciences, Inc. (IDXG)?
What is the 3-year average ROE for Interpace Biosciences, Inc. (IDXG)?
What is the 5-year average ROE for Interpace Biosciences, Inc. (IDXG)?
How does the current ROE for Interpace Biosciences, Inc. (IDXG) compare to its historical average?